Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma

Summary To determine the feasibility of liquid biopsy for monitoring of patients with advanced melanoma, cell‐free DNA was extracted from plasma for 25 Stage III/IV patients, most (84.0%) having received previous therapy. DNA concentrations ranged from 0.6 to 390.0 ng/ml (median = 7.8 ng/ml) and wer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pigment cell and melanoma research Jg. 31; H. 1; S. 73 - 81
Hauptverfasser: Gangadhar, Tara C., Savitch, Samantha L., Yee, Stephanie S., Xu, Wei, Huang, Alexander C., Harmon, Shannon, Lieberman, David B., Soucier, Devon, Fan, Ryan, Black, Taylor A., Morrissette, Jennifer J. D., Salathia, Neeraj, Waters, Jill, Zhang, Shile, Toung, Jonathan, Hummelen, Paul, Fan, Jian‐Bing, Xu, Xiaowei, Amaravadi, Ravi K., Schuchter, Lynn M., Karakousis, Giorgos C., Hwang, Wei‐Ting, Carpenter, Erica L.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Wiley Subscription Services, Inc 01.01.2018
Schlagworte:
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Biopsy
Cell-Free Nucleic Acids - blood
Cell-Free Nucleic Acids - genetics
cell‐free circulating tumor DNA
Correlation analysis
Deoxyribonucleic acid
DNA
Feasibility
Feasibility Studies
Female
Gene sequencing
High-Throughput Nucleotide Sequencing
Humans
liquid biopsy
Male
Melanoma
Melanoma - blood
Melanoma - diagnosis
Melanoma - genetics
Middle Aged
Monitoring
Mutation
Patients
Pilot Projects
precision medicine
Skin Neoplasms - blood
Skin Neoplasms - diagnosis
Skin Neoplasms - genetics
Therapy
melanoma
precision medicine
cell-free circulating tumor DNA
liquid biopsy
ISSN:1755-1471, 1755-148X, 1755-148X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary To determine the feasibility of liquid biopsy for monitoring of patients with advanced melanoma, cell‐free DNA was extracted from plasma for 25 Stage III/IV patients, most (84.0%) having received previous therapy. DNA concentrations ranged from 0.6 to 390.0 ng/ml (median = 7.8 ng/ml) and were positively correlated with tumor burden as measured by imaging (Spearman rho = 0.5435, p = .0363). Using ultra‐deep sequencing for a 61‐gene panel, one or more mutations were detected in 12 of 25 samples (48.0%), and this proportion did not vary significantly for patients on or off therapy at the time of blood draw (52.9% and 37.5% respectively; p = .673). Sixteen mutations were detected in eight different genes, with the most frequent mutations detected in BRAF, NRAS, and KIT. Allele fractions ranged from 1.1% to 63.2% (median = 29.1%). Among patients with tissue next‐generation sequencing, nine of 11 plasma mutations were also detected in matched tissue, for a concordance of 81.8%.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:1755-1471
1755-148X
1755-148X
DOI:10.1111/pcmr.12623